MRSA Causing Infections in Hospitals in Greater Metropolitan New York: Major Shift in the Dominant Clonal Type between 1996 and 2014.
A surveillance study in 1996 identified the USA100 clone (ST5/SCCmecII)-also known as the "New York/Japan" clone-as the most prevalent MRSA causing infections in 12 New York City hospitals. Here we update the epidemiology of MRSA in seven of the same hospitals eighteen years later in 2013/14. Most of the current MRSA isolates (78 of 121) belonged to the MRSA clone USA300 (CC8/SCCmecIV) but the USA100 clone-dominant in the 1996 survey-still remained the second most frequent MRSA (25 of the 121 isolates) causing 32% of blood stream infections. The USA300 clone was most common in skin and soft tissue infections (SSTIs) and was associated with 84.5% of SSTIs compared to 5% caused by the USA100 clone. Our data indicate that by 2013/14, the USA300 clone replaced the New York/Japan clone as the most frequent cause of MRSA infections in hospitals in Metropolitan New York. In parallel with this shift in the clonal type of MRSA, there was also a striking change in the types of MRSA infections from 1996 to 2014.
Laboratory of Microbiology & Infectious Diseases, The Rockefeller University, New York, New York, United States of America.
Maria
M
Pardos de la Gandara
Laboratory of Microbiology & Infectious Diseases, The Rockefeller University, New York, New York, United States of America.
Marie
M
Curry
Division of Infectious Diseases, Saint Barnabas Hospital, Bronx, New York, New York, United States of America.
Judith
J
Berger
Department of Pathology, Richmond University Medical Center, Staten Island, New York, United States of America.
David
D
Burstein
Department of Pathology and Cell Biology, Columbia University Medical Center, New York Presbyterian Hospital, New York, New York, United States of America.
Phyllis
P
Della-Latta
Department of Pathology, Richmond University Medical Center, Staten Island, New York, United States of America.
Virgina
V
Kopetz
Division of Infectious Diseases, SUNY Downstate Medical Center and Kings County Hospital, Brooklyn, New York, United States of America.
John
J
Quale
Department of Pathology, Stony Brook Health Services Center, Stony Brook, New York, United States of America.
Eric
E
Spitzer
Department of Microbiology, Saint Barnabas Hospital, Bronx, New York, United States of America.
Rexie
R
Tan
The Dr. James J. Rahal Jr. Division of Infectious Diseases, New York-Presbyterian Queens, Flushing, New York, United States of America.
Carl
C
Urban
Department of Pathology and Clinical Laboratories, Westchester Medical Center and New York Medical College, Valhalla, New York, United States of America.
Guiqing
G
Wang
Clinical Microbiology Service, Columbia University Medical Center, New York Presbyterian Hospital, New York, New York, United States of America.
Susan
S
Whittier
Laboratory of Microbiology & Infectious Diseases, The Rockefeller University, New York, New York, United States of America.|Laboratory of Molecular Genetics, Instituto de Tecnologia Química e Biológica António Xavier (ITQB/UNL), Oeiras, Portugal.
Herminia
H
de Lencastre
Laboratory of Microbiology & Infectious Diseases, The Rockefeller University, New York, New York, United States of America.
Alexander
A
Tomasz
D000900:Anti-Bacterial Agents / Q000494:pharmacology; D015373:Bacterial Typing Techniques; D006761:Hospitals; D006801:Humans; D055624:Methicillin-Resistant Staphylococcus aureus / Q000145:classification* / Q000235:genetics / Q000302:isolation & purification; D008826:Microbial Sensitivity Tests; D058889:Molecular Typing; D009518:New York / Q000453:epidemiology; D018461:Soft Tissue Infections / Q000382:microbiology*; D013203:Staphylococcal Infections / Q000453:epidemiology* / Q000382:microbiology; D013207:Staphylococcal Skin Infections / Q000382:microbiology*
D000900:Anti-Bacterial Agents